Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760263 · ClinicalTrials.gov registry record · Phase 4
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
A Phase 4 study of Transplant;Failure,Kidney, sponsored by Sentara Norfolk General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03760263: Completed Phase 4 study of Transplant;Failure,Kidney, sponsored by Sentara Norfolk General Hospital.
NCT03760263 is a Phase 4 study of Transplant;Failure,Kidney that has completed, run by Sentara Norfolk General Hospital. The registered enrollment target is 46 participants, below the 218-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760263, a Phase 4 study of Transplant;Failure,Kidney, has completed, sponsored by Sentara Norfolk General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Primary Outcome
Labs will be drawn at weekly clinic visits for the first month, every other week for the second month, then a minimum of monthly through 6 months post transplant. Labs drawn will include tacrolimus level to determine if trough levels are within target ranges according to the site's center specific tacrolimus protocol.
Conditions Studied
Interventions
- DRUG Tacrolimus
Study Locations (1)
Virginia
- Sentara Norfolk General Hospital - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 4 |
What the finished NCT03760263 record still lists
NCT03760263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 218-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Transplant;Failure,Kidney appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus is the first listed.
NCT03760263 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03760263 about?
NCT03760263 is a clinical study titled "Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus". Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
What is the current status of trial NCT03760263?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2020-01-16. Estimated completion is 2023-11-01.
What conditions does trial NCT03760263 study?
This clinical trial studies the following conditions: Transplant;Failure,Kidney.
What interventions are being tested in trial NCT03760263?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT03760263?
This trial is sponsored by Sentara Norfolk General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760263 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant;Failure,Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03760263's enrollment target sits among peer trials
46 6th of 8 higher than 3 of 8 other Transplant;Failure,Kidney trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Transplant;Failure,Kidney trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
RECRUITING · Phase 4
-
Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
COMPLETED · Phase 4
-
Abdominal Wall Transplant
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
RECRUITING · NA
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI